Acevedo, R. and Romeu, Belkis and Zayas, C. and Gonzalez, E and Lastre, M and del Campo, J and Mullen, A and Ferro, Valerie and Perez, O (2012) In vitro study of protein release from AFCo1 and implications in mucosal immunisation. VacciMonitor, 21 (2). ISSN 1025-028XFull text not available in this repository. (Request a copy from the Strathclyde author)
Adjuvant Finlay Cochleate 1 (AFCo1) is a Proteoliposome-derived cochleate obtained from Neisseria meningitidis serogroup B. Transformation of proteoliposomes into AFCo1 potentiates the immune response on Neisseria antigens when it is administered by intranasal or intragastric (i.g) routes. However, the i.n route has been demonstrated to be more effective. The aim of this work is to evaluate in vitro the protein release from AFCo1, in simulated gastric fluid (SGF) or simulated nasal fluid (SNF) using a microdissolution test and to provide support for the results found when AFCo1 was administered by i.g or i.n routes in BALB/c mice. Results showed that dilution of AFCo1 in simulated gastric fluid affects the delivery of Neisseria protein antigens because they were released from cochleate structures faster than when simulated nasal fluid was used. In conclusion, conditions simulating gastric environment affect the delivery of protein antigens from AFCo1 and this result could partially explain why i.n administration is more effective in vivo than i.g immunisation.
|Keywords:||ucosal immunisation , in vitro study , proteins, cochleate, neisseria, proteoliposome, adjuvant, Therapeutics. Pharmacology, Molecular Medicine, Drug Discovery, Immunology, Immunology and Allergy|
|Subjects:||Medicine > Therapeutics. Pharmacology|
|Department:||Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences|
|Depositing user:||Pure Administrator|
|Date Deposited:||03 Jul 2012 13:28|
|Last modified:||04 May 2016 21:54|